Live Breaking News & Updates on Antiviral drug

Stay informed with the latest breaking news from Antiviral drug on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Antiviral drug and stay connected to the pulse of your community

Why covid patients who could most benefit from paxlovid still aren't getting it

Evangelical minister Eddie Hyatt believes in the healing power of prayer but "also the medical approach." So on a February evening a week before scheduled prostate surgery, he had his sore throat checked out at an emergency room near his home in Grapevine, Texas.

United-states , Texas , American , Americans , Karl-steinberg , Xavier-becerra , William-schaffner , Eddie-hyatt , David-gifford , Chanapa-tantibanchachai , Michael-barnett , Department-of-veterans-affairs

Increased paxlovid use could lead to significant hospitalization reductions and cost savings

Increased use of Paxlovid, the antiviral drug used to treat COVID-19, could prevent hundreds of thousands of hospitalizations and save tens of billions of dollars a year, according to a new epidemiological model published by researchers at The University of Texas at Austin.

Texas , United-states , Lin-wang , Hainan , China , Hong-kong , Kobe , Hyogo , Japan , University-of-hong-kong , Hong-kong-general- , Cambridge

Letters to the Editor: These readers got COVID. Their cost for Paxlovid? At least $1,000

These readers tested positive for COVID and were told their insurance doesn't cover the antiviral drug Paxlovid, which would cost them at least $1,000.

Thousand-oaks , California , United-states , Manhattan-beach , Mike-moersen , Margarete-obrien , Aetna , Blue-shield , Blue-cross , Medicare-parts , Antiviral-drug , Ovid

Promising influenza drug candidate shows activity against resistant variants

Influenza A viruses with induced resistance to a new candidate antiviral drug were found to be impaired in cell culture and weakened in animals, according to a study by researchers in the Center for Translational Antiviral Research at Georgia State University.

Georgia , United-states , Georgia-state-university , Emory-university-school-of-medicine , Alexanderl-greninger , Elizabethb-sobolik , Michaelg-natchus , Jeong-joong-yoon , Robertm-cox , Richard-plemper , Megha-aggarwal , Nicolea-lieberman

FASEB and NIH Announce 2023 DataWorks! Prize Recipients

The Federation of American Societies for Experimental Biology (FASEB) and the Office of Data Science Strategy at the National Institutes of Health (NIH) announc

United-states , Daniel-harris , John-chodera , Kristen-briney , Karen-yook , Maryellen-giger , Andreia-vanconcellos-faria , Alexander-vanhelene , University-of-kentucky , University-of-chicago , Maryellen-giger-team , Linkedin

usfda: Zydus gets USFDA nod for antiviral drug used in HIV treatment

Zydus Lifesciences obtained final clearance from the USFDA for Darunavir Tablets, an antiviral medication used in treating HIV-1 infection. Darunavir, a protease inhibitor, restricts HIV-1 multiplication and is prescribed for adults and pediatric patients over three years old. Co-administration with Ritonavir and other antiretroviral agents is necessary. Manufactured in Ahmedabad, Gujarat, the medication holds significant market potential, recording USD 275 million in annual US sales.

Ahmedabad , Gujarat , India , Drug-administration , Zydus-lifesciences , Darunavir-tablets , Human-immunodeficiency-virus , Usfda , Us-food-and-drug-administration , Antiviral-drug , Hiv-treatment

Over 20% Of COVID Patients Treated With Paxlovid Suffer Virologic Rebound: Study

Over 20% of patients taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, suffer from the rebound, compared to less than the 2% chance seen in other treatment groups, a Harvard Medical

Jonathan-li , Mark-siedner , Harvard-medical-school , Post-vaccination-viral-characteristics-study , Covid-19 , Covid-rebound , Paxlovid , Antiviral-drug , Virologic-rebound ,

Willow bark may be the source of a new antiviral drug

Scientists have found that specially processed samples of willow bark extract have an antiviral effect which isn’t seen in already known medical compounds from willow bark, such as salicylic acid, the precursor to modern aspirin.

Finland , Varpu-marjom , Lily-ramsey , University-of-jyv , Prof-varpu-marjom , Antiviral-drug , Spirin , Ssay , Ell , Old , Ovid-19 , Lu

Another problem with daylight saving time: The time change raises your risk of hitting deer on the road

The likelihood of hitting a deer is highest during morning and evening twilight. Patrick Pleul/Picture alliance via Getty ImagesDaylight saving time ends in the U.S. and Canada on Nov. 5, 2023, and most of us will set our clocks back an hour. There is a long-running debate about the benefit of the time change, given how it disrupts humans’ circadian rhythms, causing short-term stress and fatigue. Another risk accompanying the time change is on the roads: As more people drive at dusk during an ac

Canada , Clarkson-university , New-york , United-states , West-virginia , Montana , Pennsylvania , America , Nimanthi-abeyrathna , Tom-langen , Victor-colino-rabanal , North-america